Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy

Supplemental Digital Content is available in the text.

[1]  E. Ammirati,et al.  Biventricular Intravascular Microaxial Blood Pumps and Immunosuppression as a Bridge to Recovery in Giant Cell Myocarditis , 2020, JACC. Case reports.

[2]  G. Veronese,et al.  Fulminant myocarditis triggered by OC43 subtype coronavirus: a disease deserving evidence-based care bundles. , 2020, Journal of cardiovascular medicine.

[3]  Roberto Maroldi,et al.  Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). , 2020, JAMA cardiology.

[4]  N. Chou,et al.  Prognostic factors for heart recovery in adult patients with acute fulminant myocarditis and cardiogenic shock supported with extracorporeal membrane oxygenation. , 2020, Journal of critical care.

[5]  S. Rizzo,et al.  Ventricular Arrhythmias in Myocarditis: Characterization and Relationships With Myocardial Inflammation. , 2020, Journal of the American College of Cardiology.

[6]  L. Potena,et al.  Viral genome search in myocardium of patients with fulminant myocarditis , 2020, European journal of heart failure.

[7]  L. Cooper,et al.  Recognition and Initial Management of Fulminant Myocarditis , 2020, Circulation.

[8]  G. Pontone,et al.  Prognostic Value of Repeating Cardiac Magnetic Resonance in Patients With Acute Myocarditis. , 2019, Journal of the American College of Cardiology.

[9]  R. Brunken,et al.  Infliximab for Refractory Cardiac Sarcoidosis. , 2019, The American journal of cardiology.

[10]  R. Beigel,et al.  Epidemiology characteristics and outcome of patients with clinically diagnosed acute myocarditis. , 2019, The American journal of medicine.

[11]  L. Gula,et al.  Cardiac Sarcoidosis multi-center randomized controlled trial (CHASM CS- RCT). , 2019, American heart journal.

[12]  C. Tschöpe,et al.  Immunosuppression in inflammatory cardiomyopathy and parvovirus B19 persistence , 2019, European journal of heart failure.

[13]  J. Afilalo,et al.  Diagnostic and prognostic value of cardiac magnetic resonance in acute myocarditis: a systematic review and meta-analysis , 2019, The International Journal of Cardiovascular Imaging.

[14]  A. Faron,et al.  Comparison of Original and 2018 Lake Louise Criteria for Diagnosis of Acute Myocarditis: Results of a Validation Cohort. , 2019, Radiology. Cardiothoracic imaging.

[15]  L. Potena,et al.  Fulminant Versus Acute Nonfulminant Myocarditis in Patients With Left Ventricular Systolic Dysfunction. , 2019, Journal of the American College of Cardiology.

[16]  J. Banner,et al.  Sudden cardiac death caused by myocarditis in persons aged 1–49 years: a nationwide study of 14 294 deaths in Denmark , 2019, Forensic sciences research.

[17]  Marc P. Bonaca,et al.  Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology , 2019, Circulation.

[18]  James A. White,et al.  Natural History of Myocardial Injury and Chamber Remodeling in Acute Myocarditis. , 2019, Circulation. Cardiovascular imaging.

[19]  Douglas B. Johnson,et al.  Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis. , 2019, The New England journal of medicine.

[20]  N. Johnson,et al.  Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy. , 2019, The New England journal of medicine.

[21]  D. Burkhoff,et al.  Trends in the Incidence of In-Hospital Mortality, Cardiogenic Shock, and Utilization of Mechanical Circulatory Support Devices in Myocarditis (Analysis of National Inpatient Sample Data, 2005-2014). , 2019, Journal of cardiac failure.

[22]  M. Bramerio,et al.  Recurrent cardiac sarcoidosis after heart transplantation , 2019, Clinical Research in Cardiology.

[23]  Vinay Prasad,et al.  Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs , 2019, JAMA network open.

[24]  E. Lipson,et al.  Cardiovascular toxicities associated with immune checkpoint inhibitors , 2019, Cardiovascular research.

[25]  B. Gersh,et al.  Cardiac magnetic resonance in patients with elevated troponin and normal coronary angiography , 2019, Heart.

[26]  R. Manka,et al.  Non-steroidal anti-inflammatory drug use in acute myopericarditis: 12-month clinical follow-up , 2019, Open Heart.

[27]  R. Hui,et al.  A life support-based comprehensive treatment regimen dramatically lowers the in-hospital mortality of patients with fulminant myocarditis: a multiple center study , 2019, Science China Life Sciences.

[28]  Matthias Gutberlet,et al.  Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. , 2018, Journal of the American College of Cardiology.

[29]  Marc P. Bonaca,et al.  Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. , 2018, The Lancet. Oncology.

[30]  O. Davini,et al.  Prevalence and Prognostic Impact of Septal Late Gadolinium Enhancement in Acute Myocarditis With or Without Preserved Left Ventricular Function. , 2018, The American journal of cardiology.

[31]  L. Cooper,et al.  Management and outcomes of cardiac sarcoidosis: a 20‐year experience in two tertiary care centres , 2018, European journal of heart failure.

[32]  Michael J Ackerman,et al.  2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2018, Journal of the American College of Cardiology.

[33]  G. Veronese,et al.  Acute and Fulminant Myocarditis: a Pragmatic Clinical Approach to Diagnosis and Treatment , 2018, Current Cardiology Reports.

[34]  William J. Bryant,et al.  2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. , 2018, Circulation.

[35]  C. Giannattasio,et al.  Clinical Presentation and Outcome in a Contemporary Cohort of Patients With Acute Myocarditis: Multicenter Lombardy Registry , 2018, Circulation.

[36]  M. Atkins,et al.  Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin. , 2018, Journal of immunotherapy.

[37]  D. Burkhoff,et al.  Mechanical Unloading by Fulminant Myocarditis: LV-IMPELLA, ECMELLA, BI-PELLA, and PROPELLA Concepts , 2018, Journal of Cardiovascular Translational Research.

[38]  E. Missov,et al.  A Case of Fulminant Lymphocytic Myocarditis Responsive to Immunosuppression. , 2018, The American journal of medicine.

[39]  S. Bokhari,et al.  Myocarditis in systemic lupus erythematosus diagnosed by 18F-fluorodeoxyglucose positron emission tomography , 2018, Lupus Science & Medicine.

[40]  M. Salerno,et al.  Diagnostic Performance of Extracellular Volume, Native T1, and T2 Mapping Versus Lake Louise Criteria by Cardiac Magnetic Resonance for Detection of Acute Myocarditis: A Meta-Analysis , 2018, Circulation. Cardiovascular imaging.

[41]  R. Sullivan,et al.  Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. , 2018, Journal of the American College of Cardiology.

[42]  Bénédicte Lebrun-Vignes,et al.  Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis , 2018, The Lancet.

[43]  I. Palacios,et al.  Comparison of Utilization Trends, Indications, and Complications of Endomyocardial Biopsy in Native Versus Donor Hearts (from the Nationwide Inpatient Sample 2002 to 2014). , 2018, The American journal of cardiology.

[44]  W. O’Neill,et al.  The Impella Microaxial Flow Catheter Is Safe and Effective for Treatment of Myocarditis Complicated by Cardiogenic Shock: An Analysis From the Global cVAD Registry. , 2017, Journal of cardiac failure.

[45]  F. Ageron,et al.  Management of chest pain in the French emergency healthcare system: the prospective observational EPIDOULTHO study , 2017, European journal of emergency medicine : official journal of the European Society for Emergency Medicine.

[46]  Y. Sakata,et al.  Diagnosis, medical treatment, and stepwise mechanical circulatory support for fulminat myocarditis , 2018, Journal of Artificial Organs.

[47]  K. Klingel,et al.  Eosinophilic Myocarditis: Characteristics, Treatment, and Outcomes. , 2017, Journal of the American College of Cardiology.

[48]  G. Pontone,et al.  Cardiac MR With Late Gadolinium Enhancement in Acute Myocarditis With Preserved Systolic Function: ITAMY Study. , 2017, Journal of the American College of Cardiology.

[49]  R. Blankstein,et al.  Prognostic Value of Cardiac Magnetic Resonance Tissue Characterization in Risk Stratifying Patients With Suspected Myocarditis. , 2017, Journal of the American College of Cardiology.

[50]  L. Cooper,et al.  Joint SNMMI–ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring , 2017, Journal of Nuclear Cardiology.

[51]  Shao‐Wei Chen,et al.  Heart Failure and Mortality of Adult Survivors from Acute Myocarditis Requiring Intensive Care Treatment - A Nationwide Cohort Study , 2017, International journal of medical sciences.

[52]  J. Hare,et al.  Inflammatory Cardiomyopathic Syndromes. , 2017, Circulation research.

[53]  S. Ghio,et al.  Survival and Left Ventricular Function Changes in Fulminant Versus Nonfulminant Acute Myocarditis , 2017, Circulation.

[54]  Guilherme H M Oliveira,et al.  Heart Transplantation in Giant Cell Myocarditis: Analysis of the United Network for Organ Sharing Registry. , 2017, Journal of cardiac failure.

[55]  G. Espinosa,et al.  Oxigenador extracorpóreo de membrana eficaz en una paciente con miocarditis lúpica fulminante , 2017 .

[56]  J. Casanova,et al.  Autosomal Recessive Cardiomyopathy Presenting as Acute Myocarditis. , 2017, Journal of the American College of Cardiology.

[57]  N. Ohte,et al.  Clinical impact of the presence of macrophages in endomyocardial biopsies of patients with dilated cardiomyopathy , 2017, European journal of heart failure.

[58]  C. Giannattasio,et al.  Quantitative changes in late gadolinium enhancement at cardiac magnetic resonance in the early phase of acute myocarditis. , 2017, International journal of cardiology.

[59]  M. Isobe,et al.  Factors and values at admission that predict a fulminant course of acute myocarditis: data from Tokyo CCU network database , 2017, Heart and Vessels.

[60]  G. Espinosa,et al.  Successful Extracorporeal Membrane Oxygenation in a Patient With Fulminant Lupus Myocarditis. , 2017, Revista espanola de cardiologia.

[61]  C. Yancy,et al.  Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association. , 2016, Circulation.

[62]  K. Salmenkivi,et al.  Long‐term outcome and its predictors in giant cell myocarditis , 2016, European journal of heart failure.

[63]  F. Oliva,et al.  Giant cell myocarditis successfully treated with antithymocyte globuline and extracorporeal membrane oxygenation for 21 days. , 2016, Journal of cardiovascular medicine.

[64]  S. Heymans,et al.  Relevance of cardiac parvovirus B19 in myocarditis and dilated cardiomyopathy: review of the literature , 2016, European journal of heart failure.

[65]  J. Seidman,et al.  Fulminant Myocarditis with Combination Immune Checkpoint Blockade. , 2016, The New England journal of medicine.

[66]  B. Maron,et al.  Demographics and Epidemiology of Sudden Deaths in Young Competitive Athletes: From the United States National Registry. , 2016, The American journal of medicine.

[67]  K. Waki,et al.  Clinical Features of Acute and Fulminant Myocarditis in Children　- 2nd Nationwide Survey by Japanese Society of Pediatric Cardiology and Cardiac Surgery. , 2016, Circulation journal : official journal of the Japanese Circulation Society.

[68]  S. Russell,et al.  Lack of Relationship Between Serum Cardiac Troponin I Level and Giant Cell Myocarditis Diagnosis and Outcomes. , 2016, Journal of cardiac failure.

[69]  R. Fimmers,et al.  Comprehensive Cardiac Magnetic Resonance for Short‐Term Follow‐Up in Acute Myocarditis , 2016, Journal of the American Heart Association.

[70]  E. Arbustini,et al.  Betaferon in chronic viral cardiomyopathy (BICC) trial: Effects of interferon-β treatment in patients with chronic viral cardiomyopathy , 2016, Clinical Research in Cardiology.

[71]  O. Alfieri,et al.  Venoarterial Extracorporeal Membrane Oxygenation for Acute Fulminant Myocarditis in Adult Patients: A 5-Year Multi-Institutional Experience. , 2016, The Annals of thoracic surgery.

[72]  A. Neumayr,et al.  Toxocariasis-associated cardiac diseases--A systematic review of the literature. , 2016, Acta tropica.

[73]  M. Goddard,et al.  Alemtuzumab as a novel treatment for refractory giant cell myocarditis after heart transplantation. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[74]  A. Ha,et al.  Cardiac Sarcoidosis. , 2016, Journal of the American College of Cardiology.

[75]  J. Garot,et al.  Cardiovascular magnetic resonance predictors of clinical outcome in patients with suspected acute myocarditis , 2015, Journal of Cardiovascular Magnetic Resonance.

[76]  N. Banner,et al.  Usefulness of Rabbit Anti-thymocyte Globulin in Patients With Giant Cell Myocarditis. , 2015, The American journal of cardiology.

[77]  Dan J Stein,et al.  Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[78]  M. J. Oliva-Sandoval,et al.  Genetics of myocarditis in arrhythmogenic right ventricular dysplasia. , 2015, Heart rhythm.

[79]  R. Dreyer,et al.  Systematic Review of Patients Presenting With Suspected Myocardial Infarction and Nonobstructive Coronary Arteries , 2015, Circulation.

[80]  J. Airaksinen,et al.  Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. , 2015, Circulation.

[81]  W. Edwards,et al.  Electrogram guidance: a method to increase the precision and diagnostic yield of endomyocardial biopsy for suspected cardiac sarcoidosis and myocarditis. , 2014, JACC. Heart failure.

[82]  N. Rose.  Learning from myocarditis: mimicry, chaos and black holes , 2014, F1000prime reports.

[83]  M. Ackerman,et al.  Pathogeneses of Sudden Cardiac Death in National Collegiate Athletic Association Athletes , 2014, Circulation. Arrhythmia and electrophysiology.

[84]  G. Barbati,et al.  Long-Term Evolution and Prognostic Stratification of Biopsy-Proven Active Myocarditis , 2013, Circulation.

[85]  Tiina Heliö,et al.  Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2013, European heart journal.

[86]  Y. Shoenfeld,et al.  Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. , 2013, Autoimmunity reviews.

[87]  S. Russell,et al.  Evaluation of the Role of Endomyocardial Biopsy in 851 Patients With Unexplained Heart Failure From 2000–2009 , 2013, Circulation. Heart failure.

[88]  K. Salmenkivi,et al.  Diagnosis, Treatment, and Outcome of Giant-Cell Myocarditis in the Era of Combined Immunosuppression , 2013, Circulation. Heart failure.

[89]  G. Schuler,et al.  Diagnostic performance of CMR imaging compared with EMB in patients with suspected myocarditis. , 2012, JACC. Cardiovascular imaging.

[90]  K. Klingel,et al.  Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. , 2012, Journal of the American College of Cardiology.

[91]  Sandeep Sagar,et al.  Myocarditis , 2012, The Lancet.

[92]  P. Croisille,et al.  Churg-Strauss syndrome presenting with acute myocarditis and cardiogenic shock. , 2012, Heart, lung & circulation.

[93]  L. Cooper,et al.  Response to alemtuzumab in FIP1L1/PDGFRA-negative hypereosinophilic myocarditis on serial cardiac magnetic resonance imaging. , 2012, Journal of the American College of Cardiology.

[94]  Eric A. Shry,et al.  Sudden death in young adults: an autopsy-based series of a population undergoing active surveillance. , 2011, Journal of the American College of Cardiology.

[95]  M. Kupari,et al.  Cardiac Sarcoidosis and Giant Cell Myocarditis as Causes of Atrioventricular Block in Young and Middle-Aged Adults , 2011, Circulation. Arrhythmia and electrophysiology.

[96]  K. Klingel,et al.  Human parvovirus B19-associated myocarditis. , 2010, The New England journal of medicine.

[97]  P. Grossfeld,et al.  Fulminant myocarditis associated with pandemic H1N1 influenza A virus in children. , 2010, Journal of the American College of Cardiology.

[98]  S. Markowitz.  Human Parvovirus B 19 – Associated Myocarditis , 2010 .

[99]  Andrea Frustaci,et al.  Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. , 2009, European heart journal.

[100]  Matthias Gutberlet,et al.  Cardiovascular Magnetic Resonance in Myocarditis: A JACC White Paper , 2009 .

[101]  E. Arbustini,et al.  The role of endomyocardial biopsy in the management of cardiovascular disease: a commentary on joint AHA/ACC/ESC guidelines , 2009, Heart.

[102]  K. Bailey,et al.  Usefulness of immunosuppression for giant cell myocarditis. , 2008, The American journal of cardiology.

[103]  Michael Böhm,et al.  Predictors of Outcome in Patients With Suspected Myocarditis , 2008, Circulation.

[104]  Renu Virmani,et al.  A Scientific Statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology , 2022 .

[105]  G. Freeman,et al.  Endothelial Programmed Death-1 Ligand 1 (PD-L1) Regulates CD8+ T-Cell–Mediated Injury in the Heart , 2007, Circulation.

[106]  A. Angelini,et al.  A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. , 2007, European heart journal.

[107]  S. Colan,et al.  Incidence, causes, and outcomes of dilated cardiomyopathy in children. , 2006, JAMA.

[108]  J. Magnani,et al.  Survival in biopsy-proven myocarditis: a long-term retrospective analysis of the histopathologic, clinical, and hemodynamic predictors. , 2006, American heart journal.

[109]  H. Chen,et al.  Corticosteroids for viral myocarditis. , 2006, The Cochrane database of systematic reviews.

[110]  D. Gary Gilliland,et al.  The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management , 2004 .

[111]  Jan Cools,et al.  The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. , 2004, Blood.

[112]  S. Kato,et al.  Changes in the peripheral eosinophil count in patients with acute eosinophilic myocarditis , 2003, Heart and Vessels.

[113]  K. Bailey,et al.  A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis. , 2003, Journal of the American College of Cardiology.

[114]  D. Corrado,et al.  Sudden cardiac death in young people with apparently normal heart. , 2001, Cardiovascular research.

[115]  A. Ristic,et al.  Definition of Inflammatory Cardiomyopathy (Myocarditis): On the Way to Consensus A Status Report , 2000, Herz.

[116]  K. Klingel,et al.  Molecular Pathology and Structural Features of Enteroviral Replication Toward Understanding the Pathogenesis of Viral Heart Disease , 2000, Herz.

[117]  R. Hruban,et al.  Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. , 2000, The New England journal of medicine.

[118]  G. Berry,et al.  Idiopathic giant-cell myocarditis--natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. , 1997, The New England journal of medicine.

[119]  B Maisch,et al.  Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. , 1996, Circulation.

[120]  H. Schultheiss,et al.  Immunohistological evidence for a chronic intramyocardial inflammatory process in dilated cardiomyopathy. , 1996, Heart.

[121]  B. McManus,et al.  A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. , 1995, The New England journal of medicine.

[122]  K. Bailey,et al.  Long-term outcome of patients with biopsy-proved myocarditis: comparison with idiopathic dilated cardiomyopathy. , 1995, Journal of the American College of Cardiology.

[123]  S. Colan,et al.  Gamma-globulin treatment of acute myocarditis in the pediatric population. , 1994, Circulation.

[124]  B. McManus,et al.  Insensitivity of right ventricular endomyocardial biopsy in the diagnosis of myocarditis. , 1989, Journal of the American College of Cardiology.

[125]  H. Aretz.  Myocarditis: the Dallas criteria. , 1987, Human pathology.